share_log

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo在肝脏会议上重点介绍了FXR314在MASH中的2期结果,显示相比其他FXR激动剂,具有显著的肝脂减少和改善的安全性概况。
Benzinga ·  11/20 21:08

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo在肝脏大会上重点介绍了FXR314在MASH的2期结果,显示与其他FXR激动剂相比,具有显著的降低肝脂和改善安全性的优势

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发